Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Jan. 31, 2020
Jan. 31, 2019
Revenue
Operating costs and expenses:    
Amortization of patents 251,250
Research and development expenses (including non-cash share-based compensation expenses of $397,523 and $1,573,779, respectively) 1,490,588 2,247,272
General and administrative expenses (including non-cash share-based compensation expenses of $623,811 and $1,176,385, respectively) 1,139,281 2,066,456
Impairment in carrying amount of patent asset 418,750
Total operating costs and expenses 2,629,869 4,983,728
Loss from operations (2,629,869) (4,983,728)
Interest income 13,294 17,119
Loss before income taxes (2,616,575) (4,966,609)
Provision for income taxes
Net loss (2,616,575) (4,966,609)
Less: Net loss attributable to noncontrolling interest (24,032) (84,768)
Net loss attributable to common shareholders $ (2,592,543) $ (4,881,841)
Net loss per common share attributable to common shareholders:    
Basic and diluted (in Dollars per share) $ (0.13) $ (0.25)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 20,703,882 19,170,591